Drug Profile
KS 01018
Alternative Names: KS 01 018Latest Information Update: 12 Sep 2007
Price :
$50
*
At a glance
- Originator Kos Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Peripheral arterial disorders
Most Recent Events
- 13 Dec 2006 Kos Pharmaceuticals has been acquired by Abbott Laboratories
- 14 Jun 2005 Phase-III clinical trials in Peripheral arterial disorders in USA (PO)
- 07 Sep 2004 Phase-II/III clinical trials in Peripheral arterial disorders in USA (PO)